ArticleFrontiers in immunology2021

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.

Kiwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.